A consortium of mostly European laboratories is in the midst of investigating new markers for hematological cancers using amplicon deep sequencing.

The research study, called IRON-II, for Interlaboratory Robustness of Next-generation sequencing, is supported by Roche and uses the 454 platform. A follow-on to an earlier study to test the technical performance of amplicon deep sequencing in different laboratories, the new study is investigating panels of one to 25 genes in a total of 6,000 to 8,000 retrospective samples covering five hematological malignancies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.